Apalutamide and Overall Survival in Prostate Cancer

Matthew R. Smith; Fred Saad; Simon Chowdhury; Stéphane Oudard; Boris A. Hadaschik; Julie N. Graff; David Olmos; Paul N. Mainwaring; Ji Youl Lee; Hiroji Uemura; Peter De Porre; Andressa A. Smith; Sabine D. Brookman-May; Susan Li; Ke Zhang; Brendan Rooney; Angela Lopez-Gitlitz; Eric J. Small

doi:10.1016/j.eururo.2020.08.011

Apalutamide and Overall Survival in Prostate Cancer

Matthew R. Smith, Fred Saad, Simon Chowdhury, Stéphane Oudard, Boris A. Hadaschik, Julie N. Graff, David Olmos, Paul N. Mainwaring, Ji Youl Lee, Hiroji Uemura, Peter De Porre, Andressa A. Smith, Sabine D. Brookman-May, Susan Li, Ke Zhang, Brendan Rooney, Angela Lopez-Gitlitz, Eric J. Small

Research output: Contribution to journal › Article › peer-review

201 Scopus citations

Abstract

Apalutamide increased overall survival and delayed time to initiation of cytotoxic chemotherapy versus placebo in patients with nonmetastatic castration-resistant prostate cancer. Prior analyses had demonstrated clinically impactful improvement in metastasis-free survival, time to symptomatic progression, and second progression-free survival with apalutamide.

Original language	English
Pages (from-to)	150-158
Number of pages	9
Journal	European Urology
Volume	79
Issue number	1
DOIs	https://doi.org/10.1016/j.eururo.2020.08.011
State	Published - Jan 2021

Bibliographical note

Funding Information:
Funding/Support and role of the sponsor : The trial was designed by two of the academic authors and representatives of the Aragon Pharmaceuticals. The sponsor commissioned an independent data and safety monitoring committee to review safety data the results of the primary efficacy analysis before unblinding. Data were transcribed, by trial personnel at each clinical site, from source documents into electronic case-report forms prepared by the sponsor. All the authors had access to the data, drafted the manuscript with input from the sponsor (Janssen), reviewed and approved the manuscript before submission, and made the decision to submit the manuscript for publication. The SPARTAN study was funded by Janssen Research & Development . Janssen Global Services, LLC provided funding for editorial assistance.

Publisher Copyright:
© 2020 The Authors

Keywords

Apalutamide
Nonmetastatic castration-resistant prostate cancer
Overall survival
Subsequent therapy
Time to cytotoxic chemotherapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.eururo.2020.08.011

Cite this

Smith, M. R., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B. A., Graff, J. N., Olmos, D., Mainwaring, P. N., Lee, J. Y., Uemura, H., De Porre, P., Smith, A. A., Brookman-May, S. D., Li, S., Zhang, K., Rooney, B., Lopez-Gitlitz, A., & Small, E. J. (2021). Apalutamide and Overall Survival in Prostate Cancer. European Urology, 79(1), 150-158. https://doi.org/10.1016/j.eururo.2020.08.011

@article{d9bc2d38d9444b14b63981b40cfc4337,

title = "Apalutamide and Overall Survival in Prostate Cancer",

abstract = "Apalutamide increased overall survival and delayed time to initiation of cytotoxic chemotherapy versus placebo in patients with nonmetastatic castration-resistant prostate cancer. Prior analyses had demonstrated clinically impactful improvement in metastasis-free survival, time to symptomatic progression, and second progression-free survival with apalutamide.",

keywords = "Apalutamide, Nonmetastatic castration-resistant prostate cancer, Overall survival, Subsequent therapy, Time to cytotoxic chemotherapy",

author = "Smith, {Matthew R.} and Fred Saad and Simon Chowdhury and St{\'e}phane Oudard and Hadaschik, {Boris A.} and Graff, {Julie N.} and David Olmos and Mainwaring, {Paul N.} and Lee, {Ji Youl} and Hiroji Uemura and {De Porre}, Peter and Smith, {Andressa A.} and Brookman-May, {Sabine D.} and Susan Li and Ke Zhang and Brendan Rooney and Angela Lopez-Gitlitz and Small, {Eric J.}",

note = "Funding Information: Funding/Support and role of the sponsor : The trial was designed by two of the academic authors and representatives of the Aragon Pharmaceuticals. The sponsor commissioned an independent data and safety monitoring committee to review safety data the results of the primary efficacy analysis before unblinding. Data were transcribed, by trial personnel at each clinical site, from source documents into electronic case-report forms prepared by the sponsor. All the authors had access to the data, drafted the manuscript with input from the sponsor (Janssen), reviewed and approved the manuscript before submission, and made the decision to submit the manuscript for publication. The SPARTAN study was funded by Janssen Research & Development . Janssen Global Services, LLC provided funding for editorial assistance. Publisher Copyright: {\textcopyright} 2020 The Authors",

year = "2021",

month = jan,

doi = "10.1016/j.eururo.2020.08.011",

language = "English",

volume = "79",

pages = "150--158",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "1",

}

TY - JOUR

T1 - Apalutamide and Overall Survival in Prostate Cancer

AU - Smith, Matthew R.

AU - Saad, Fred

AU - Chowdhury, Simon

AU - Oudard, Stéphane

AU - Hadaschik, Boris A.

AU - Graff, Julie N.

AU - Olmos, David

AU - Mainwaring, Paul N.

AU - Lee, Ji Youl

AU - Uemura, Hiroji

AU - De Porre, Peter

AU - Smith, Andressa A.

AU - Brookman-May, Sabine D.

AU - Li, Susan

AU - Zhang, Ke

AU - Rooney, Brendan

AU - Lopez-Gitlitz, Angela

AU - Small, Eric J.

N1 - Funding Information: Funding/Support and role of the sponsor : The trial was designed by two of the academic authors and representatives of the Aragon Pharmaceuticals. The sponsor commissioned an independent data and safety monitoring committee to review safety data the results of the primary efficacy analysis before unblinding. Data were transcribed, by trial personnel at each clinical site, from source documents into electronic case-report forms prepared by the sponsor. All the authors had access to the data, drafted the manuscript with input from the sponsor (Janssen), reviewed and approved the manuscript before submission, and made the decision to submit the manuscript for publication. The SPARTAN study was funded by Janssen Research & Development . Janssen Global Services, LLC provided funding for editorial assistance. Publisher Copyright: © 2020 The Authors

PY - 2021/1

Y1 - 2021/1

N2 - Apalutamide increased overall survival and delayed time to initiation of cytotoxic chemotherapy versus placebo in patients with nonmetastatic castration-resistant prostate cancer. Prior analyses had demonstrated clinically impactful improvement in metastasis-free survival, time to symptomatic progression, and second progression-free survival with apalutamide.

AB - Apalutamide increased overall survival and delayed time to initiation of cytotoxic chemotherapy versus placebo in patients with nonmetastatic castration-resistant prostate cancer. Prior analyses had demonstrated clinically impactful improvement in metastasis-free survival, time to symptomatic progression, and second progression-free survival with apalutamide.

KW - Apalutamide

KW - Nonmetastatic castration-resistant prostate cancer

KW - Overall survival

KW - Subsequent therapy

KW - Time to cytotoxic chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=85090311385&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2020.08.011

DO - 10.1016/j.eururo.2020.08.011

M3 - Article

C2 - 32907777

AN - SCOPUS:85090311385

SN - 0302-2838

VL - 79

SP - 150

EP - 158

JO - European Urology

JF - European Urology

IS - 1

ER -

Apalutamide and Overall Survival in Prostate Cancer

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this